Several Wall Street banks have raised their price targets for SpaceX, with Morgan Stanley increasing its target to $300.
Several Wall Street banks raised their price targets for SpaceX after the release of its earnings report, with Morgan Stanley increasing its target to $300, Wells Fargo to $274 (previously $214), Citi to $240 (previously $200), UBS to $230 (previously $210), and Mizuho to $205 (previously $200).
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Oracle, Meta, and SpaceX credit default swaps (CDS) hit all-time highs, as the market anticipates a surge in AI-related bond issuance in Q4.
-
2
Bain Survey: Chinese Consumers Prioritize Technology in Car Purchases, While Europeans and Americans Still Value Price; Western Automakers Face Dual Pressure
-
3
Media reports: Amazon Web Services (AWS) has billions of dollars worth of NVIDIA chips backlogged in its warehouses due to power shortages, leading to negative free cash flow.
-
4
Multi-party talks between the US and Ukraine were held in Oslo, Norway, with the Finnish President stating "real progress has been made." Russia hopes to meet with the US envoy on the 21st.
-
5
Liu Jun, President of Industrial and Commercial Bank of China (ICBC): Commercial Banks Bear Heavier Financial and Legal Responsibilities Than Central Banks in AI Deployment
-
6
Anthropic pitches AI safety bill that would require judge's permission to block models
-
7
Anthropic reportedly faces a compute shortage as cloud giants view it as a competitor, plans November IPO.
-
8
NextDC's data center project in Australia faces power supply delays due to resident protests, leading to a more than one-third reduction in its FY2027 earnings guidance and a 45% plunge in its stock price.
-
9
King Charles III of the UK praised Oman's peaceful efforts in reopening the Strait of Hormuz.
-
10
Hansoh Pharmaceutical inks up to $15B drug deal with Roche, China's innovative drug out-licensing hits $130B
Markets Today
Recommended Reading


